Clearmind Medicine Inc. has finished enrolling six patients in the second cohort of its FDA‑approved Phase I/IIa study of CMND‑100, an oral therapy for Alcohol Use Disorder. The cohort was recruited at Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, underscoring the company’s ability to secure participation at high‑profile sites.
The CMND‑100 trial is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with moderate to severe AUD. Completion of the second cohort marks a critical milestone that will allow the company to begin dosing the cohort, collect additional safety data, and move toward top‑line results that will inform future regulatory submissions.
CEO Dr. Adi Zuloff‑Shani said the accelerated pace of enrollment reflects strong interest from patients and clinicians, and he highlighted the company’s confidence that CMND‑100 could transform AUD treatment. "We are thrilled with the accelerated pace of enrollment for our second cohort," he said, adding that the enthusiasm from leading clinical sites signals a promising path forward.
Clearmind’s focus on neuroplastogen‑derived therapeutics positions it in a $20 billion global AUD treatment market. The company holds 31 granted patents across 19 families, and it has recently completed a 1‑for‑40 reverse stock split to meet Nasdaq bid‑price requirements. While operating at a loss—negative EBITDA of $5.79 million over the last twelve months—the company maintains a current ratio of 1.32 and continues to invest in clinical development.
With dosing for the second cohort slated to begin shortly, Clearmind expects top‑line data in the coming months. The results will be pivotal for determining the next phase of development and for establishing the safety and efficacy profile needed to support a future FDA approval and commercial launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.